Itraconazole is Effective in the Treatment of Tinea Capitis Caused by Microsporum Canis

Tinea capitis is a relatively common superficial fungal infection in children which requires oral antifungal therapy. In a prospective, open study over 24 weeks, itraconazole 5 mg/kg/day, given as capsules or as an oral suspension for a period of 2–12 weeks, was used to treat children 1–12 years of age who had M. canis tinea capitis. Children with mycologic evidence of M. canis tinea capitis were entered into the study and asked to return at week 2 and then every 2 weeks thereafter until cured, with a maximum of 12 weeks of active treatment. At each visit the scalp was sampled and the material processed for light microscopy and culture examination. An extra 2 weeks of itraconazole was prescribed if the mycology from the sample obtained on the previous visit indicated that there was still presence of the organism. Patients were administered either 2, 4, 6, 8, 10, or 12 weeks of treatment. The final follow‐up visit was at 12 weeks from the cessation of drug therapy. Laboratory blood testing was performed only if indicated by history, examination, or the development of side effects. There were 107 patients (49 boys, 58 girls; mean ± standard error = 5.6 ± 0.2 years). Thirteen of the 107 children were given the oral suspension. At week 12 from the cessation of treatment there was complete (clinical and mycologic) cure in all 107 children. Increasing age of the patient correlated significantly with the length of itraconazole capsule therapy (p = 0.03). The duration of itraconazole treatment also correlated significantly with the severity of tinea capitis at baseline (p = 0.02). Adverse effects were observed in 5 children receiving itraconazole capsules (n = 94). These were regarded as being possibly or probably due to the drug in two children (mild transient stomach ache in one and moderate diarrhea in one). The child with diarrhea stopped therapy at week 4 with complete resolution of symptoms. One of 13 children receiving the oral suspension had mild, transient diarrhea. There were no drop‐outs in this group. Laboratory testing was not required in any patient. Compliance was very good in the patient group. Itraconazole 5 mg/kg/day given either as a capsule or an oral suspension for 4–8 weeks is effective and safe in the treatment of tinea capitis caused by M. canis.

[1]  R. Summerbell,et al.  Once weekly fluconazole is effective in children in the treatment of tinea capitis: a prospective, multicentre study , 2000, The British journal of dermatology.

[2]  H. Degreef,et al.  The Use of Itraconazole to Treat Cutaneous Fungal Infections in Children , 1999, Dermatology.

[3]  C. Romano Tinea capitis in Siena, Italy. An 18‐year survey , 1999, Mycoses.

[4]  W. Sterry,et al.  Case Report. Osteomyelitis caused by high resistant Candida guilliermondii , 1999, Mycoses.

[5]  A. Gupta,et al.  Itraconazole oral solution for the treatment of tinea capitis using the pulse regimen. , 1999, Cutis.

[6]  R. Summerbell,et al.  Tinea Capitis: An Overview with Emphasis on Management , 1999, Pediatric dermatology.

[7]  Bräutigam,et al.  Short duration treatment with terbinafine for tinea capitis caused by Trichophyton or Microsporum species , 1999, The British journal of dermatology.

[8]  W. Sterry,et al.  Tinea capitis in Germany. A survey in 1998. , 1999, Mycoses.

[9]  Haroon,et al.  A double‐blind, randomized, comparative trial of itraconazole versus terbinafine for 2 weeks in tinea capitis , 1998, The British journal of dermatology.

[10]  R. Summerbell,et al.  Treatment of tinea capitis with itraconazole capsule pulse therapy. , 1998, Journal of the American Academy of Dermatology.

[11]  Gupta,et al.  Itraconazole oral solution for the treatment of tinea capitis , 1998, The British journal of dermatology.

[12]  R. Summerbell,et al.  Increased incidence of Trichophyton tonsurans tinea capitis in Ontario, Canada between 1985 and 1996 , 1998 .

[13]  R. Summerbell,et al.  Increased incidence of Trichophyton tonsurans tinea capitis in Ontario, Canada between 1985 and 1996. , 1998, Medical mycology.

[14]  V. Dragoš,et al.  Lack of Efficacy of 6‐Week Treatment with Oral Terbinafine for Tinea Capitis Due to Microsporum canis in Children , 1997, Pediatric dermatology.

[15]  G. Ginter Microsporum canis infections in children: results of a new oral antifungal therapy , 1996, Mycoses (Berlin).

[16]  M. Cuétara,et al.  ITRACONAZOLE VERSUS GRISEOFULVIN IN THE TREATMENT OF TINEA CAPITIS: A DOUBLE‐BLIND RANDOMIZED STUDY IN CHILDREN , 1994, International journal of dermatology.